MLTX MoonLake Immunotherapeutics
- Stocks
- Healthcare
- NASDAQ: MLTX
Price (delayed)
$10.59
Market cap
$680.2M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.78
Enterprise value
$449.29M
Relative Growth:
Rel. Growth:
0
Relative Strength:
Rel. Strength:
0
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
2
moonlake immunotherapeutics ag is a clinical-stage biopharmaceutical company leveraging revolutionary nanobody® technology to develop next-level medicines for immunologic diseases, including inflammatory skin and joint diseases.
Highlights
MLTX's quick ratio has dropped by 63% year-on-year and by 22% since the previous quarter
MLTX's equity is down by 32% YoY and by 13% QoQ
Key stats
What are the main financial stats of MLTX
Market
Valuations
Earnings
Shares outstanding
64.23M
Market cap
$680.2M
Enterprise value
$449.29M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.92
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$200.88M
Net income
-$179.12M
EBIT
-$176.68M
EBITDA
-$174.23M
Free cash flow
-$166.76M
Per share
Balance sheet
Liquidity
EPS
-$2.78
EPS diluted
-$2.78
Free cash flow per share
-$2.64
Book value per share
$5.51
Revenue per share
$0
TBVPS
$7.27
Total assets
$460.1M
Total liabilities
$102.15M
Debt
$75.77M
Equity
$353.73M
Working capital
$428.12M
Debt to equity
0.21
Current ratio
16.65
Quick ratio
15.66
Net debt/EBITDA
1.33
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-36.4%
Return on equity
-42.2%
Return on invested capital
-78.8%
Return on capital employed
-40.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MLTX stock price
How has the MoonLake Immunotherapeutics stock price performed over time
Intraday
4.54%
1 week
10.2%
1 month
25.62%
1 year
-77.77%
YTD
-80.44%
QTD
47.7%
Financial performance
How have MoonLake Immunotherapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$200.88M
Net income
-$179.12M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 156% year-on-year and by 18% since the previous quarter
The net income has declined by 21% since the previous quarter
Price vs fundamentals
How does MLTX's price correlate with its fundamentals
Growth
What is MoonLake Immunotherapeutics's growth rate over time
Valuation
What is MoonLake Immunotherapeutics stock price valuation
P/E
N/A
P/B
1.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
MoonLake Immunotherapeutics's EPS has decreased by 21% QoQ
The price to book (P/B) is 74% lower than the last 4 quarters average of 7.3
MLTX's equity is down by 32% YoY and by 13% QoQ
Efficiency
How efficient is MoonLake Immunotherapeutics business performance
The ROIC has plunged by 82% YoY and by 19% from the previous quarter
The company's return on equity fell by 33% QoQ
The company's return on assets fell by 26% QoQ
Dividends
What is MLTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MLTX.
Financial health
How did MoonLake Immunotherapeutics financials performed over time
MLTX's quick ratio has dropped by 63% year-on-year and by 22% since the previous quarter
The current ratio has dropped by 62% year-on-year and by 21% since the previous quarter
The debt is 79% smaller than the equity
MLTX's equity is down by 32% YoY and by 13% QoQ
MoonLake Immunotherapeutics's debt to equity has increased by 11% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.